NASDAQ
NLSP

NLS Pharmaceutics AG

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

NLS Pharmaceutics AG Stock Price

Vitals

Today's Low:
$0.86
Today's High:
$0.9568
Open Price:
$0.896
52W Low:
$0.4201
52W High:
$1.88
Prev. Close:
$0.8828
Volume:
44174

Company Statistics

Market Cap.:
$36.03 million
Book Value:
0.101
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-128.67%
Return on Equity TTM:
-862.92%

Company Profile

NLS Pharmaceutics AG had its IPO on 2021-01-29 under the ticker symbol NLSP.

The company operates in the Healthcare sector and Biotechnology industry. NLS Pharmaceutics AG has a staff strength of 0 employees.

Stock update

Shares of NLS Pharmaceutics AG opened at $0.9 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.86 - $0.96, and closed at $0.87.

This is a -1.46% slip from the previous day's closing price.

A total volume of 44,174 shares were traded at the close of the day’s session.

In the last one week, shares of NLS Pharmaceutics AG have slipped by -26.9%.

NLS Pharmaceutics AG's Key Ratios

NLS Pharmaceutics AG has a market cap of $36.03 million, indicating a price to book ratio of 25.7772 and a price to sales ratio of 0.

In the last 12-months NLS Pharmaceutics AG’s revenue was $0 with a gross profit of $0 and an EBITDA of $-15470956. The EBITDA ratio measures NLS Pharmaceutics AG's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, NLS Pharmaceutics AG’s operating margin was 0% while its return on assets stood at -128.67% with a return of equity of -862.92%.

In Q2, NLS Pharmaceutics AG’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

NLS Pharmaceutics AG’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.94 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NLS Pharmaceutics AG’s profitability.

NLS Pharmaceutics AG stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.6108. Its price to sales ratio in the trailing 12-months stood at 0.

NLS Pharmaceutics AG stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$9.28 million
Total Liabilities
$3.36 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

NLS Pharmaceutics AG ended 2024 with $9.28 million in total assets and $0 in total liabilities. Its intangible assets were valued at $9.28 million while shareholder equity stood at $3.28 million.

NLS Pharmaceutics AG ended 2024 with $0 in deferred long-term liabilities, $3.36 million in other current liabilities, 668555.00 in common stock, $-58201455.00 in retained earnings and $0 in goodwill. Its cash balance stood at $8.95 million and cash and short-term investments were $8.95 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

NLS Pharmaceutics AG’s total current assets stands at $9.25 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $41243.00 compared to accounts payable of $2.37 million and inventory worth $0.

In 2024, NLS Pharmaceutics AG's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, NLS Pharmaceutics AG paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.87
52-Week High
$1.88
52-Week Low
$0.4201
Analyst Target Price
$7.83

NLS Pharmaceutics AG stock is currently trading at $0.87 per share. It touched a 52-week high of $1.88 and a 52-week low of $1.88. Analysts tracking the stock have a 12-month average target price of $7.83.

Its 50-day moving average was $0.93 and 200-day moving average was $1.19 The short ratio stood at 0.89 indicating a short percent outstanding of 0%.

Around 3848.4% of the company’s stock are held by insiders while 1993.9% are held by institutions.

Frequently Asked Questions About NLS Pharmaceutics AG

The stock symbol (also called stock or share ticker) of NLS Pharmaceutics AG is NLSP

The IPO of NLS Pharmaceutics AG took place on 2021-01-29

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$2.84
-0.01
-0.35%
Dollarama Inc (DLMAF)
$64.78
0.55
+0.86%
$39.03
0.98
+2.58%
$200.2
-9.45
-4.51%
James Warren Tea Ltd (JAMESWARREN)
$249.65
0.6
+0.24%
$45.76
-0.66
-1.42%
$2.75
-0.11
-3.85%
$5.47
-0.04
-0.73%
$4.78
0
0%
$47
2
+4.44%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Address

The Circle 6, Zurich, Switzerland, 8058